Allogene Therapeutics, Inc. Share Price & Technical Analysis
ALLO · $1.96 (+3.16%)
Healthcare / Biotechnology
$1.96
+3.16%
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. T…
Price chart
Seasonality
May has 0 positive and 5 negative years (last 5 years shown)
-5% return in May, -15% avg return in past 3 year May month.
56% return in 2026, -27% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 29% | 56% | -8% | -16% | -5% | – | – | – | – | – | – | – | 56% |
| 25 | -18% | 11% | -21% | 21% | -29% | -8% | 9% | -8% | 9% | 0% | 25% | 0% | -10% |
| 24 | 9% | 40% | -8% | -36% | -11% | -8% | 26% | -13% | 8% | -7% | -4% | -16% | -20% |
| 23 | 18% | -18% | -27% | 10% | -4% | -4% | 2% | -20% | -18% | -12% | -18% | 39% | -51% |
| 22 | -23% | -21% | 0% | -9% | -5% | 44% | 14% | 7% | -21% | -7% | -6% | -36% | -62% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$798.73M
P/E ratio
—
52W high
$4.46
52W low
$0.98
Volume
43,27,267
Beta
0.46
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Allogene Therapeutics, Inc. share price today?
- Allogene Therapeutics, Inc. (ALLO) last traded around $1.96 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ALLO have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ALLO. Download the app for real-time alerts.
- How can I analyze Allogene Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.